TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29566698
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health intervention program from infancy to age 5 years.
Study: 29566762
Drug: CyberKnife accelerated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyberKnife accelerated partial breast irradiation (CK-APBI) with 30 Gy in five fractions, treatment time approximately 60 min (range 35 to 120 min).
Study: 29567071
Drug: Adjuvant fluorouracil-based
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant fluorouracil-based chemotherapy after D2 gastrectomy (n=193)
Study: 29567071
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy plus surgery (n=323)
Study: 29567774
Drug: Lenalidomide, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide, dosage and duration not available
Study: 29568374
Drug: Folate receptor-targeted
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate receptor-targeted intraoperative molecular imaging (FR-IMI) with OTL38
Study: 29569246
Drug: 3T3-J2 feeder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3T3-J2 feeder cell culture with Y-27632 (ROCK inhibitor) in conditional reprograming conditions (CRC)
Study: 29570971
Drug: CYP2D6 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2D6 and fluoxetine
Study: 29570971
Drug: CYP2C19 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2C19 and sertraline
Study: 29570971
Drug: CYP2B6 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2B6 and sertraline
Study: 29571854
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate 40 mg three times a week
Study: 29571854
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate 20 mg daily
Study: 29571946
Drug: Nilotinib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilotinib (400 mg twice per day)
Study: 29572391
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of donor-derived CD8
Study: 29572709
Drug: Pasireotide LAR
Normalized name: pasireotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide LAR 60 mg/m for at least 6 months
Study: 29572709
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with everolimus 10 mg/d
Study: 29573889
Drug: Broccoli sprouts
Normalized name: broccoli sprout extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli sprouts (30 g/day) for 10 weeks
Study: 29574070
Drug: Pitavastatin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin (4 mg/d)
Study: 29574465
Drug: Oral HIV
Normalized name: HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HIV test
Study: 29574497
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with CKD (albuminuria ≥ 30 mg/day)
Study: 29574497
Drug: Patients aged
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients aged ≥ 75 years with albuminuria < 10 mg/day
Study: 29574622
Drug: 7.5 mg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/week MTX + adalimumab
Study: 29574622
Drug: 20 mg/week
Normalized name: selinexor 60 mg twice weekly (120 mg/week) (20 mg x 6) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/week MTX + adalimumab
Study: 29576341
Drug: Human bone
Normalized name: Allogeneic human bone marrow-derived mpc
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human bone marrow-derived stem cells (BMDSCs) infusion
Study: 29576341
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of BMDSCs and their CD133+ fraction
Study: 29578248
Drug: Bupivacaine dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine dosage
Study: 29578250
Drug: Vasopressin infusion
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin infusion 4.8 U/h
Study: 29578250
Drug: Vasopressin infusion
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin infusion combined with nitroglycerin infusion
Study: 29578646
Drug: Lamotrigine 25
Normalized name: lamotrigine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine 25 to 100 mg once daily
Study: 29579214
Drug: Temocillin 1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temocillin 1, 2 or 3 g (total of 61 doses)
Study: 29579214
Drug: New temocillin
Normalized name: temocillin
DrugBank: Temocillin (DB12343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New temocillin dosage regimen (not specified in detail)
Study: 29579214
Drug: Currently licensed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Currently licensed dosage regimen
Study: 29584546
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg every 2 weeks until disease progression/unacceptable toxicity
Study: 29587672
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment initiation
Study: 29587672
Drug: Switching antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching antidepressants
Study: 29587677
Drug: OTS-GC-A24 cancer
Normalized name: OT-730
DrugBank: OT-730 (DB16112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTS-GC-A24 cancer vaccine at 1 mg administered in 3-weekly (3w), 2-weekly (2w), and weekly (1w) cohorts.
Study: 29587759
Drug: Regular pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular pain medication intake
Study: 29587807
Drug: Group-based Acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based Acceptance and Commitment Therapy (ACT)
Study: 29587808
Drug: SRP in
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP in combination with 400 mg MTZ + 500 mg AMX, starting at the first SRP session (active phase group)
Study: 29587808
Drug: SRP in
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP in combination with 400 mg MTZ + 500 mg AMX, starting after 3 months of its completion (healing phase group)
Study: 29588304
Drug: Very low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Very low-dose rivaroxaban added to DAPT (ASA + clopidogrel or ASA + ticagrelor)
Study: 29590008
Drug: Chemotherapy (investigator's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (investigator's choice, e.g., docetaxel 75 mg/m2)
Study: 29590311
Drug: Primaquine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine 0.5 mg/kg/day for 14 days
Study: 29590325
Drug: Low alcohol
Normalized name: Low alcohol beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low alcohol detection threshold (BrAC = 0.025 mg/l, BACSwe = 0.05‰ or US = 0.0053g/dl)
Study: 29590401
Drug: Intravenous injections
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injections of (S,S)-[11C]O-methylreboxetine ([11C]MRB) during hypoglycemia
Study: 29592869
Drug: Monthly $60-per-child
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly $60-per-child benefit
Study: 29592869
Drug: Monthly $30-per-child
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly $30-per-child benefit
Study: 29592876
Drug: Third-party fecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-party fecal microbiota transplantation (FMT) capsules administered no later than 4 weeks after neutrophil engraftment.
Study: 29593099
Drug: Pilaralisib tablets
Normalized name: Pilaralisib
DrugBank: Pilaralisib (DB11772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilaralisib tablets (400 mg once daily)
Study: 29594201
Drug: Lung FDG
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung FDG uptake (measured by SUVmax, SUVmean, SUVpeak, and GLG) after concurrent chemoradiation (CRT)
Study: 29594970
Drug: Anti-TNF agents
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF agents (monotherapy or combination)
Study: 29595064
Drug: Venetoclax monotherapy;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax monotherapy; specific dosage and duration not mentioned.
Study: 29595064
Drug: Venetoclax followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax followed by the addition of chemotherapy; specific chemotherapy regimen not mentioned.
Study: 29598861
Drug: Conventional Biological
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Biological Valves (CBV)
Study: 29598891
Drug: Open surgical
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open surgical treatment (all patients combined)
Study: 29599068
Drug: Diuretic exposure
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic exposure
Study: 29599068
Drug: No diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No diuretic exposure (Control)
Study: 29599200
Drug: First-line treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line treatment (specifics not provided)
Study: 29599200
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow transplantation (consolidation treatment)
Study: 29600824
Drug: Norepinephrine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine monotherapy
Study: 29601256
Drug: MenABCWY+OMV booster
Normalized name: Omvoh
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenABCWY+OMV booster (1 dose for Group III, 2 doses for Groups VI and VII)
Study: 29601256
Drug: MenABCWY+OMV (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenABCWY+OMV (2 doses)
Study: 29601268
Drug: Concurrent aerobic
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent aerobic and strength training, three 60-minute sessions per week from the 17th gestational week until delivery
Study: 29602767
Drug: Dual loading
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual loading antiplatelet therapy with aspirin and P2Y
Study: 29603015
Drug: Ulixertinib (BVD-523)
Normalized name: BVdU
DrugBank: Ulixertinib (DB13930)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulixertinib (BVD-523) at a recommended phase 2 dose of 600 mg BID
Study: 29603017
Drug: Home-wearable light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-wearable light therapy for 60 min daily for 5 weeks
Study: 29603017
Drug: Home-wearable light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-wearable light therapy
Study: 29603764
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose lenalidomide (10 mg) plus dexamethasone (Rdex)
Study: 29605216
Drug: High ICS
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High ICS doses
Study: 29606148
Drug: Standard Speech
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Speech and Language Therapy (usual care)
Study: 29606415
Drug: Alirocumab 75mg
Normalized name: ALIROCUMAB 75MG/ML INJ 1ML SYR
DrugBank: Alirocumab (DB09302)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Alirocumab 75mg every 2 weeks (Q2W) added to statin therapy (atorvastatin ≥10mg/day or rosuvastatin ≥5mg/day), with a potential increase to 150mg Q2W if LDL-C remains ≥100mg/dL at week 12.
Study: 29606415
Drug: Standard-of-care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (SOC) with atorvastatin ≥10mg/day or rosuvastatin ≥5mg/day, with dose adjustment to achieve LDL-C <100mg/dL.
Study: 29606586
Drug: Larotrectinib, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larotrectinib, administered orally (capsule or liquid), twice daily on a continuous 28-day schedule, in increasing doses adjusted for age and bodyweight. Doses included 100 mg twice daily (cohort 1) and 150 mg twice daily (cohort 2).
Study: 29606665
Drug: Combination ETN
Normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination ETN plus csDMARD
Study: 29607050
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg UDCA for 12 weeks followed by 50 mg sitagliptin for 12 weeks (UDCA-first group)
Study: 29607050
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sitagliptin for 12 weeks followed by 900 mg UDCA for 12 weeks (sitagliptin-first group)
Study: 29607050
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg UDCA
Study: 29608587
Drug: Flolan (epoprostenol)
Normalized name: epoprostenol Injection [Flolan]
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flolan (epoprostenol) solution prepared with the reformulated pH 12.0 diluent
Study: 29608587
Drug: Flolan (epoprostenol)
Normalized name: epoprostenol Injection [Flolan]
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flolan (epoprostenol) solution prepared with the existing pH 10.5 diluent
Study: 29609013
Drug: Bimekizumab (64
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimekizumab (64 mg, 160 mg, 320 mg, 480 mg)
Study: 29609532
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitors (TKIs) discontinuation with regular monitoring
Study: 29610115
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m2), Lenalidomide, Ibrutinib
Study: 29610121
Drug: ERBB3-Directed Targeted
Normalized name: DIRECT BLUE 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERBB3-Directed Targeted Therapy
Study: 29610659
Drug: CCLG group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCLG group (chemotherapy with less local treatment)
Study: 29610659
Drug: GPOH group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPOH group (chemotherapy with more local treatment)
Study: 29611022
Drug: GSK2141795 (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2141795 (75 mg daily)
Study: 29614955
Drug: G allele
Approvals — FDA: no, EMA: no, PMDA: no
Description: G allele of SNP rs2528795 in ELN gene
Study: 29614997
Drug: Study-specific questionnaires
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study-specific questionnaires measuring level of knowledge about disease and treatment.
Study: 29616236
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control group (monthly household visits to measure child mid-upper arm circumference)
Study: 29617001
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (personalized based on ARR10 benefit threshold)
Study: 29617001
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (personalized based on ARR10 benefit threshold ≥2.3%)
Study: 29617822
Drug: Dolutegravir maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir maintenance monotherapy
Study: 29618159
Drug: New generation
Approvals — FDA: no, EMA: no, PMDA: no
Description: New generation P2Y12 inhibitors
Study: 29619634
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 3 grams daily
Study: 29622037
Drug: SAM-760 30
Normalized name: SAM
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAM-760 30 mg once daily for 12 weeks
Study: 29622159
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation at discharge
Study: 29622168
Drug: Low-Dose Ticagrelor
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-Dose Ticagrelor
Study: 29622168
Drug: Standard-Dose Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-Dose Ticagrelor
Study: 29622527
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (weekly phone-based notifications)
Study: 29622755
Drug: Febuxostat (xanthine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (xanthine oxidase inhibitor) for 6 months, lowering serum UA to <6 mg/dL
Study: 29622755
Drug: Febuxostat (xanthine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (xanthine oxidase inhibitor) for 6 months
Study: 29624558
Drug: Cefixime 800
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefixime 800 mg
Study: 29624558
Drug: Cefixime 1200
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefixime 1200 mg
Study: 29624558
Drug: Cefixime 800
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefixime 800 mg every 8 hours × 3 doses (total dose 2400 mg)
Study: 29624882
Drug: No vaccine
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: No vaccine coverage
Study: 29625571
Drug: Automated telephone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated telephone self-management (ATSM) queries for diabetes, blood pressure, and cholesterol pills
Study: 29625579
Drug: Self-matching to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-matching to treatment options
Study: 29625579
Drug: Expert-matching to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expert-matching to treatment options
Study: 29625622
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (standard hospital treatment)
Study: 29626135
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of multiple burr hole procedure under local anesthesia and intravenous erythropoietin pretreatment
Study: 29626424
Drug: Multifocal nitrous
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifocal nitrous oxide cryoballoon ablation (CbFAS) with a dose of 10 seconds of spray per site, repeated every 10 to 12 weeks for a maximum of 5 treatments.
Study: 29628312
Drug: ALT-803 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALT-803 (20 μg/kg subcutaneously once per week) in combination with nivolumab (240 mg intravenously every 14 days)
Study: 29628397
Drug: Enhanced labile
Normalized name: Eucalyptus Leaf (Eucalyptus Globulus Labill.)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced labile plasma iron (eLPI) measured in serum samples with the FeROS eLPI kit; values greater than 0.4 μmol/L considered raised eLPI.
Study: 29628397
Drug: eLPI as
Approvals — FDA: no, EMA: no, PMDA: no
Description: eLPI as a biological mediator of iron-related toxicity.
Study: 29629190
Drug: Antibiotic awareness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic awareness activities
Study: 29629190
Drug: Proxy indicators
Normalized name: proxyphylline
DrugBank: Proxyphylline (DB13449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proxy indicators for detecting problematic antibiotic behaviours
Study: 29630018
Drug: Any medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any medication taken during pregnancy
Study: 29630018
Drug: Any medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any medication taken in the first trimester
Study: 29630018
Drug: Polypharmacy (taking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypharmacy (taking at least five medications)
Study: 29630018
Drug: Medications taken
Normalized name: salicylic acid Medicated Liquid Soap [Take Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications taken during pregnancy (excluding vitamins, supplements, and vaccines)
Study: 29630018
Drug: Medications taken
Normalized name: salicylic acid Medicated Liquid Soap [Take Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications taken in the first trimester (excluding vitamins, supplements, and vaccines)
Study: 29630018
Drug: Gastrointestinal or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrointestinal or antiemetic agents
Study: 29631584
Drug: Circulating sex
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Circulating sex hormones (testosterone, DHEA-S, estrogen, progesterone)
Study: 29631615
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow mesenchymal stem cell (BMMSC) transplantation therapy
Study: 29632533
Drug: M72/AS01 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: M72/AS01 vaccine administered in two doses (30 days apart)
Study: 29632720
Drug: PD-1 blockade
Normalized name: Recombinant pd-1 mab cs1003
DrugBank: Nofazinlimab (DB18852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 blockade (knockout or antibody blockade)
Study: 29635147
Drug: Intrathecal trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal trastuzumab (150 mg)
Study: 29635147
Drug: Intrathecal trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal trastuzumab (60 mg or higher)
Study: 29635415
Drug: PrEP (preexposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrEP (preexposure prophylaxis) offered to participants; specific dosage and duration not mentioned.
Study: 29635876
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) therapy at a maintenance dose of 1.0 g/kg every 3 weeks for 52 weeks.
Study: 29636030
Drug: Two-stage surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-stage surgical strategy (debridement-negative pressure therapy and flap coverage) with prolonged antimicrobial therapy